Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals (APLS)
:APLS
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 781.37M | $ 396.59M | $ 75.42M | $ 66.56M | $ 250.65M |
| Gross Profit | $ 663.64M | $ 338.08M | $ 69.79M | $ 61.36M | $ 225.60M |
| Operating Income | $ -164.98M | $ -517.12M | $ -594.61M | $ -536.28M | $ -213.73M |
| EBITDA | $ -154.53M | $ -495.21M | $ -617.39M | $ -731.27M | $ -312.23M |
| Net Income | $ -197.88M | $ -528.63M | $ -652.17M | $ -746.35M | $ -344.87M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 411.29M | $ 352.30M | $ 551.80M | $ 700.55M | $ 877.65M |
| Total Assets | $ 885.05M | $ 788.73M | $ 760.22M | $ 881.76M | $ 960.57M |
| Total Debt | $ 469.78M | $ 110.93M | $ 112.71M | $ 210.22M | $ 377.73M |
| Net Debt | $ 58.49M | $ -240.26M | $ -439.09M | $ -429.97M | $ -188.05M |
| Total Liabilities | $ 656.51M | $ 594.21M | $ 590.35M | $ 683.10M | $ 756.01M |
| Stockholders' Equity | $ 228.54M | $ 194.52M | $ 169.87M | $ 198.66M | $ 204.56M |
| Cash Flow | |||||
| Free Cash Flow | $ -88.27M | $ -595.51M | $ -515.27M | $ -564.23M | $ -165.91M |
| Operating Cash Flow | $ -87.87M | $ -594.74M | $ -513.75M | $ -563.13M | $ -160.49M |
| Investing Cash Flow | $ -403.00K | $ -674.00K | $ 59.89M | $ 247.62M | $ -316.99M |
| Financing Cash Flow | $ 149.24M | $ 394.50M | $ 365.66M | $ 392.24M | $ 692.18M |